多发性硬化中的共病与疾病活动性
该研究采用两阶段Meta分析方法,汇总17项多发性硬化疾病修饰治疗3期临床试验的16794例个体数据,评估共病与2年随访期间疾病活动证据的关联。结果显示,3种及以上共病、2种及以上心脏代谢疾病及1种精神障碍均与疾病活动证据风险升高相关。作者认为共病与多发性硬化疾病活动存在不良关联,预防和管理共病应是临床实践的紧迫关注点。
要点
- 17项3期试验16794例多发性硬化患者中,2年随访期间61.0%存在疾病活动证据。
- 与无共病相比,3种及以上共病与疾病活动证据风险升高相关(AHR 1.14)。
- 与无心脏代谢共病相比,2种及以上心脏代谢疾病与疾病活动证据风险升高相关(AHR 1.21)。
核心结论
- 共病负担较高与多发性硬化患者更差的临床结局相关,但共病可能只是其他负面预后因素的部分中介因素。
- 作者认为所研究的共病与多发性硬化疾病活动存在显著不良关联,预防和管理共病应是临床实践的紧迫关注点。
研究设计与样本
- 采用两阶段Meta分析方法的队列研究,使用多发性硬化疾病修饰治疗3期临床试验的个体参与者数据。
- 纳入的试验需有2年随访,实施时间为2001年11月至2018年3月。
- 共纳入17项临床试验的16794例多发性硬化参与者,其中67.2%为女性。
- 数据分析时间为2023年2月至2024年6月。
主要发现
- 2年随访期间,汇总试验中有61.0%(95%CI 56.2%-66.3%;I²=97.9%)存在疾病活动证据。
- 调整多因素后,与无共病相比,存在3种及以上共病与疾病活动证据风险升高相关(AHR 1.14;95%CI 1.02-1.28)。
- 与无心脏代谢共病相比,存在2种及以上心脏代谢疾病与疾病活动证据风险升高相关(AHR 1.21;95%CI 1.08-1.37)。
- 存在1种精神障碍与疾病活动证据风险升高相关(AHR 1.07;95%CI 1.02-1.14)。
关键数值与推荐
- 主要结局为2年随访期间的疾病活动证据,定义为确认的复发活动、残疾恶化或磁共振成像上任何新发病灶。
- 暴露为试验入组时存在的共病负担及个体共病,包括高血压、高脂血症、功能性心血管疾病、缺血性心脏病、脑血管病和外周血管病、糖尿病、自身免疫性甲状腺疾病及其他自身免疫性疾病、偏头痛、肺部和皮肤疾病、抑郁、焦虑及其他精神障碍。
临床怎么用
- 作者认为预防和管理共病应是临床实践的紧迫关注点。
局限性
- 共病可能只是其他负面预后因素的部分中介因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Multiple studies suggest that comorbidity worsens clinically relevant outcomes in multiple sclerosis (MS), including the severity of disability at diagnosis and rate of disability worsening after diagnosis. However, less is known regarding the association of comorbidity with measures of disease activity, such as relapse rate and magnetic resonance imaging lesion accrual, which are relevant to clinicians and clinical trialists. OBJECTIVE: To evaluate the association of comorbidities with disease activity in clinical trials of disease-modifying therapies (DMTs) in populations with MS. DESIGN, SETTING, AND PARTICIPANTS: A 2-stage meta-analytic approach was used in this cohort study of individual participant data from phase 3 clinical trials of MS DMTs that had 2 years of follow-up and were conducted from November 2001 to March 2018. Data were analyzed from February 2023 to June 2024. EXPOSURE: Comorbidity burden and individual comorbidities present at trial enrollment, including hypertension; hyperlipidemia; functional cardiovascular disease, ischemic heart, cerebrovascular, and peripheral vascular disease; diabetes; autoimmune thyroid and miscellaneous autoimmune conditions; migraine; lung and skin conditions; depression; anxiety; and other psychiatric disorders. MAIN OUTCOMES AND MEASURES: The main outcome was evidence of disease activity (EDA) over 2 years of follow-up, defined as confirmed relapse activity, disability worsening, or any new lesions on magnetic resonance imaging. RESULTS: A total of 16 794 participants with MS were included from 17 clinical trials (67.2% female). Over the 2-year follow-up, 61.0% (95% CI, 56.2%-66.3%; I2 = 97.9%) of the pooled trials had EDA. After adjusting for multiple factors, the presence of 3 or more comorbidities was associated with an increased hazard of EDA (adjusted hazard ratio [AHR], 1.14; 95% CI, 1.02-1.28) compared with no comorbidity. Presence of 2 or more cardiometabolic conditions was also associated with an increased hazard of EDA (AHR, 1.21; 95% CI, 1.08-1.37) compared with no cardiometabolic comorbidity. Presence of 1 psychiatric disorder was associated with an increased hazard of EDA (AHR, 1.07; 95% CI, 1.02-1.14). CONCLUSIONS AND RELEVANCE: In this study, a higher burden of comorbidity was associated with worse clinical outcomes in people with MS, although comorbidity could potentially be a partial mediator of other negative prognostic factors. Our findings suggest a substantial adverse association of the comorbidities investigated with MS disease activity and that prevention and management of comorbidities should be a pressing concern in clinical practice.
引用
- Salter A, Lancia S, Kowalec K, et al. Comorbidity and Disease Activity in Multiple Sclerosis. JAMA Neurol. 2024. PMID: 39291661. doi:10.1001/jamaneurol.2024.2920
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。